The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
EMA: Treatment for adult patients in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma - FDA: Treatment for adult patients in combination with durvalumab with unresectable hepatocellular carcinoma
Gastrointestinal Cancers
Hepatobiliary Cancers - Hepatocellular Carcinoma
-
HIMALAYA
5
PRELIMINARY SCORE
OS
5
ADJUSTMENTS
FINAL SCORE
F1
1
Pembrolizumab
-
Single arm (Phase II)
For patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.
Skin Cancers
Cutaneous Squamous Cell Carcinoma
-
KEYNOTE-629
3
ADJUSTMENTS
FINAL SCORE
F1
3
Cemiplimab
-
Single arm (Phase II)
For the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation
Skin Cancers
Cutaneous Squamous Cell Carcinoma
-
R2810-ONC-1423/R2810-ONC-1540
4
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
2
Cemiplimab
-
Investigator's choice of ChT
Indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy
Gynaecological Malignancies
Cervical Cancer
-
EMPOWER-Cervical 1
4
PRELIMINARY SCORE
OS
5
ADJUSTMENTS
FINAL SCORE
F1
2
Tremelimumab
Durvalumab and platinum-based ChT
Platinum-based ChT
EMA: First-line treatment of tremelimumab in combination with durvalumab and platinum-based chemotherapy (ChT) for adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations - FDA: Tremelimumab in combination with durvalumab and platinum-based ChT for adult patients with metastatic NSCLC with no EGFR mutation or ALK genomic tumor aberrations.
Thoracic Malignancies
Non-small-cell Lung Cancer
-
POSEIDON
4
PRELIMINARY SCORE
OS
5
ADJUSTMENTS
FINAL SCORE
F1
2
Abemaciclib
-
Single arm (Phase II)
Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer with disease progression following ET and prior ChT in the metastatic setting
Breast Cancer
Breast Cancer
HR+, HER2-
MONARCH 1
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Bevacizumab
Capecitabine
Placebo + capecitabine
First-line treatment of patients with metastatic breast cancer in whom treatment with other ChT options, including taxanes or anthracyclines, is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with bevacizumab–capecitabine
Breast Cancer
Breast Cancer
-
RIBBON-1
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Olaparib
Abiraterone and prednisone or prednisolone
Placebo + abiraterone and prednisone or prednisolone
In combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration resistant prostate cancer in whom chemotherapy is not clinically indicated
Genitourinary Cancers
Prostate cancer
-
PROpel
2
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
4
Relatlimab
Nivolumab
Nivolumab
First line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression <1%.
Melanoma
Cutaneous Melanoma
PD-L1 expression <1%
RELATIVITY-047
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Adagrasib
-
Single arm (Phase I/II)
For adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy
Thoracic Malignancies
Non-small-cell Lung Cancer
KRAS G12C
KRYSTAL-1
2
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
4
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Treatment Setting
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
esmo.mcbs.table.heading.visualisation
esmo.mcbs.table.heading.visualisation
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.